Gallium-68 satoreotide

Drug Profile

Gallium-68 satoreotide

Alternative Names: 68Ga IPN 1070; 68Ga-DOTA-JR11; 68Ga-OPS-202; 68Ga-satoreotide; OPS 202; SOMscan

Latest Information Update: 20 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OctreoPharm Sciences
  • Developer Ipsen; Memorial Sloan-Kettering Cancer Center; OctreoPharm Sciences
  • Class Imaging agents; Peptides; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroendocrine tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neuroendocrine tumours

Most Recent Events

  • 09 Jul 2017 Phase-II clinical trials in Neuroendocrine tumours (Diagnosis) in Austria (Parenteral) (EudraCT2016-004928-39)
  • 02 Jun 2017 Preliminary efficacy and adverse events data from a phase I trial in Neuroendocrine tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 06 Sep 2016 Phase-II clinical trials in Neuroendocrine tumours (Diagnosis) in Switzerland (Parenteral) before September 2016 (Ipsen pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top